Get the latest news, insights, and market updates on GRAL (GRAIL, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Jim Cramer on GRAIL: “I’m Going to Say Absolutely Not to That One”
GRAIL, Inc. (NASDAQ:GRAL) is one of the stocks Jim Cramer recently answered questions about. Responding to a caller’s question about the stock during the lightning round, Cramer remarked: “Yeah, and I just read a really good piece the other day written by Dr. Topol, who’s been on the show a number of times. It did […] Oct 24, 2025 - $GRAL
GRAIL, Inc. (GRAL): A Bull Case Theory
We came across a bullish thesis on GRAIL, Inc. on Value investing subreddit by BombasticBillionaire. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.’s share was trading at $86.41 as of October 16th. Grail (GRAL) is emerging as a leader in multi-cancer early detection (MCED) with its Galleri blood test, which leverages machine learning on DNA methylation patterns to detect signals from over 50 cancer types, including hard-to-screen cancers […] Oct 23, 2025 - $GRAL
A Fresh Look at GRAIL (GRAL) Valuation Following a Year of Strong Share Price Momentum
GRAIL (GRAL) has caught the market’s attention lately, riding a steady wave with its shares gaining over 4% in the past year. Investors are keeping an eye on the company’s recent revenue growth and how it could shape future performance. See our latest analysis for GRAIL. Momentum is clearly building for GRAIL, with a 1-month share price return of nearly 101% and an incredible year-to-date gain of 367%. While the latest day saw a pullback, the standout figure is its 1-year total shareholder... Oct 21, 2025 - $GRAL
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents' fees and other expenses. Oct 20, 2025 - $GRAL
/U P D A T E -- GRAIL, Inc./
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. Oct 18, 2025 - $GRAL
GRAIL (GRAL) Is Up 21.5% After Samsung Partnership to Expand Galleri Test in Asia – What's Changed
Samsung C&T and Samsung Electronics announced a US$110 million equity investment in GRAIL and a collaboration to commercialize the Galleri multi-cancer detection test in key Asian markets, with initial distribution exclusively in South Korea and potential expansion to Japan and Singapore. This partnership brings together GRAIL’s technology and Samsung’s commercial strength, while also opening the door for further integration of health data platforms and joint research initiatives. We’ll... Oct 17, 2025 - $GRAL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple